Literature DB >> 2429564

Modeling ion channel blockade at guarded binding sites: application to tertiary drugs.

C F Starmer, K R Courtney.   

Abstract

Excitable membranes exposed to sodium channel blocking agents (D; local anesthetics and antiarrhythmic drugs) show a progressive reduction of peak sodium current when repetitively depolarized (use dependence). Thus, with repetitive excitation, use dependence reflects a net rightward shift in the balance between unblocked channels (U) and blocked channels (B): U + D in equilibrium with B. The modulated receptor hypothesis (a 7-parameter model) has been proposed to account for this shift and is based on a channel lumen binding site whose affinity varies with channel state and where drug-complexed channels exhibit modified inactivation gate kinetics. Alternatively, we consider use-dependent binding as the result of transient access to a constant-affinity binding site. In this setting, the channel gate conformation is viewed as controlling the flux of drug as it diffuses between drug pools and the binding site. Apparent variation in binding rates is therefore considered the result of variations in the fraction of accessible sites. This guarded receptor hypothesis, with three fewer parameters, is able to predict apparent changes in channel binding and apparent shifts in channel inactivation without incorporating modified gating parameters in drug-complexed channels. Furthermore, with this model one is able to characterize both relaxation kinetics and channel blockade associated with tertiary amines as well as hydrophobic and hydrophilic agents. The pH dependence of repriming rates is utilized to estimate several of the important parameters associated with this simplified hypothesis.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2429564     DOI: 10.1152/ajpheart.1986.251.4.H848

Source DB:  PubMed          Journal:  Am J Physiol        ISSN: 0002-9513


  9 in total

1.  Kinetics of local anesthetic inhibition of neuronal sodium currents. pH and hydrophobicity dependence.

Authors:  D M Chernoff; G R Strichartz
Journal:  Biophys J       Date:  1990-07       Impact factor: 4.033

2.  Kinetic analysis of phasic inhibition of neuronal sodium currents by lidocaine and bupivacaine.

Authors:  D M Chernoff
Journal:  Biophys J       Date:  1990-07       Impact factor: 4.033

3.  The activation gate of the sodium channel controls blockade and deblockade by disopyramide in rabbit Purkinje fibres.

Authors:  R Gruber; E Carmeliet
Journal:  Br J Pharmacol       Date:  1989-05       Impact factor: 8.739

4.  Theoretical characterization of ion channel blockade. Competitive binding to periodically accessible receptors.

Authors:  C F Starmer
Journal:  Biophys J       Date:  1987-09       Impact factor: 4.033

5.  Specific mechanism of use-dependent channel block of calcium-permeable AMPA receptors provides activity-dependent inhibition of glutamatergic neurotransmission.

Authors:  A V Zaitsev; K K Kim; I M Fedorova; N A Dorofeeva; L G Magazanik; D B Tikhonov
Journal:  J Physiol       Date:  2011-04-01       Impact factor: 5.182

6.  Nicorandil shortens action potential duration and antagonises the reduction of Vmax by lidocaine but not by disopyramide in guinea-pig papillary muscles.

Authors:  M Kojima; T Ban
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1988-02       Impact factor: 3.000

7.  Characterization of cocaine-induced block of cardiac sodium channels.

Authors:  W J Crumb; C W Clarkson
Journal:  Biophys J       Date:  1990-03       Impact factor: 4.033

8.  Sodium channel-blocking properties of flecainide, a class IC antiarrhythmic drug, in guinea-pig papillary muscles. An open channel blocker or an inactivated channel blocker.

Authors:  M Kojima; T Hamamoto; T Ban
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1989-04       Impact factor: 3.000

9.  Tonic and phasic block of neuronal sodium currents by 5-hydroxyhexano-2',6'-xylide, a neutral lidocaine homologue.

Authors:  D M Chernoff; G R Strichartz
Journal:  J Gen Physiol       Date:  1989-06       Impact factor: 4.086

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.